DIALYZERS

FX CorAL® Dialyzers

FX CorAL dialyzers with Fresenius Medical Care’s most advanced membrane are designed for high middle molecule removal and albumin preservation1 during every treatment.

ASK ABOUT FX CORAL DIALYZERS

FX CorAL Delivers a Combination of Strong Clinical Performance and High Hemocompatibility*

FX CorAL dialyzers are designed for clinical performance and hemocompatibility2 with an innovative Helixone®hydro membrane composed of polysulfone with ɑ-tocopherol-stabilized polyvinylpyrrolidone (PVP).3 
Combined with INLINE steam sterilization, a lightweight dialyzer housing, and lateral blood ports, FX CorAL defines the next generation in our Fresenius Medical Care dialyzer portfolio.**


Technical Innovation

Nano-controlled spinning technology is used to give every membrane a porosity and surface architecture designed to increase middle-sized molecule removal while minimizing albumin permeability.4


INLINE Steam Sterilization

Each FX CorAL dialyzer is individually sterilized using the INLINE steam method, where both blood and dialysate compartments are rinsed with sterile water, air, and steam at a minimum of 121°C.***


Designed for Strong Clinical Performance

Clinical studies conducted with the FX CorAL have demonstrated reduced complement and leukocyte activation compared to the other dialyzers investigated.*,2,5,6

 

 

Indications for Use: FX CorAL dialyzers are intended for hemodialysis (HD), hemodiafiltration (HDF), hemofiltration (HF), and isolated ultrafiltration in patients with acute kidney injury or chronic kidney disease when conservative therapy is judged to be inadequate.

Caution: Federal (US) law restricts these devices to sale by or on the order of a physician.

Note: Read the Instructions for Use for safe and proper use of these devices. For full range of clearance and sieving results see: https://fmcna.com/products/disposables/dialyzers/fx-coral/.

Note: The applicability of a dialyzer for a particular treatment is the responsibility of the physician. In rare cases, thrombocytopenia, hypersensitivity reactions including anaphylactic or anaphylactic reactions to the dialyzer, or other elements in the extracorporeal circuit may occur during treatment.

© 2024 Fresenius Medical Care, All Rights Reserved. Fresenius Medical Care, the triangle logo, FX CorAL, Helixone, Hemoflow, and Optiflux are trademarks of Fresenius Medical Care Holdings, Inc., or its affiliated companies. All other trademark are the property of their respective owners. D/N US-FXCORAL-000003 Rev C 11/2024

References

  1. Melchior P. et al. Complement activation by dialysis membranes and its association with secondary membrane formation and surface charge. Artif Organs. 2021 Jul;45(7):770-778. doi: 10.1111/aor.13887. Epub 2021 Feb 13. PMID: 33326619.
  2. Ehlerding G. et al. Performance and Hemocompatibility of a Novel Polysulfone Dialyzer: A Randomized Controlled Trial. Kidney360. 2021 Apr 7;2(6):937-947. doi: 10.34067/KID.0000302021. PMID: 35373083; PMCID: PMC8791382.
  3. Zawada AM. et al. Polyvinylpyrrolidone in hemodialysis membranes: Impact on platelet loss during hemodialysis. Hemodial Int. 2021 Oct;25(4):498-506. doi: 10.1111/hdi.12939. Epub 2021 Jun 4. PMID: 34085391.
  4. Ronco C, et al. Does nanotechnology apply to dialysis? Blood Purif. 2001;19(4):347-52. doi: 10.1159/000046964. PMID: 11574730.
  5. Reis ES. et al. New insights into the immune functions of complement. Nat Rev Immunol. 2019 Aug;19(8):503-516. doi: 10.1038/s41577-019-0168-x. PMID: 31048789; PMCID: PMC6667284.
  6. Götz E et al. Comparison of clinical performance and hemocompatibility of dialyzers applied during post-dilution online hemodiafiltration (HDF) - Empora III Study. Nephrology Dialysis Transplantation, Volume 38, Issue Supplement_1, June 2023, gfad063c_3944, https://doi.org/10.1093/ndt/gfad063c_3944.

*Study conducted with post-dilution hemodiafiltration

**When compared to Optiflux High Flux ebeam

***Note: Blood pathway sterile only